The authors made effective use of a patient-derived iPSC model of AD by detecting a disease-relevant protein, extracellular tau (eTau), in the conditioned medium of iPSC-derived cortical neurons of AD patients, generating a therapeutic antibody against eTau [188]. This evidence concerns the gene MAPT and Alzheimer disease.